open access
Consolidation therapy in advanced non-small cell lung cancer
open access
Abstract
Pneumonol. Alergol. Pol. 2010; 78, 6: 439-444
Abstract
Pneumonol. Alergol. Pol. 2010; 78, 6: 439-444
Keywords
non-small cell lung cancer; chemotherapy; maintenance therapy; docetaxel; pemetrexed; targeted therapies


Title
Consolidation therapy in advanced non-small cell lung cancer
Journal
Advances in Respiratory Medicine
Issue
Article type
Review paper
Pages
439-444
Published online
2010-10-29
Bibliographic record
Pneumonol Alergol Pol 2010;78(6):439-444.
Keywords
non-small cell lung cancer
chemotherapy
maintenance therapy
docetaxel
pemetrexed
targeted therapies
Authors
Renata Duchnowska


- Booton R, Thatcher N. Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration. Curr Opin Oncol. 2002; 14(2): 191–198.
- Socinski MA, Baggstrom MQ, Hensing TA. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003; 1(1): 33–38.
- Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004; 350(4): 379–392.
- Socinski MA. Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. Clin Lung Cancer. 2004; 5(5): 274–289.
- Vergnenègre A. [Stage IV non-small cell lung cancer. Duration of chemotherapy for locally advanced non small cell lung cancers]. Rev Mal Respir. 2006; 23(5 Pt 3): 16S72–16S77.
- Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Curr Treat Options Oncol. 2007; 8(1): 38–46.
- Barata FJ, Parente B, Teixeira N, et al. Optimal duration of chemotherapy in non-small-cell lung cancer: multicenter, randomized, prospective clinical trial comparing 4 vs 6 cycles of carboplatin and gemcitabine. 2007; 2: S666 (supl. J. Thorac. Oncol. 2007; 2(S666): (supl.; abstr. P2–235).
- Belani CP, Brodowicz T, Ciuleanu TE, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009; 374(9699): 1432–1440.
- Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27(4): 591–598.
- Brodowicz T, Krzakowski M, Zwitter M, et al. Central European Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006; 52(2): 155–163.
- Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol. 2001; 19(5): 1336–1343.
- Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20(5): 1335–1343.
- Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21(15): 2933–2939.
- von Plessen C, Bergman B, Andresen O, et al. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer. 2006; 95(8): 966–973.
- Westeel V, Quoix E, Moro-Sibilot D, et al. French Thoracic Oncology Collaborative Group (GCOT). Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97(7): 499–506.
- Park JOh, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol. 2007; 25(33): 5233–5239.
- Soon YuY, Stockler MR, Askie LM, et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol. 2009; 27(20): 3277–3283.
- Jassem J, Drosik K, Dziadziuszko R, et al. Systemowe leczenie niedrobnokomórkowego raka płuca i złośliwego międzybłoniaka opłucnej: uaktualnione zalecenia oparte na wynikach wiarygodnych badań klinicznych. Nowotwory. 2007; 57: 71–78.
- Azzoli CG, Baker S, Temin S, et al. American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27(36): 6251–6266.
- Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006; 107(7): 1589–1596.
- Cappuzzo F, Coudert BP, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thor Oncol. 2009; 4(supl. 1): 289.
- Meerbeeck J.V. A randomized phase III study of follow up with or without adjuvant Gefitinib (Iressa TM) following chemotherapy in patients with advanced non-small cell lung cancer EORTC08021. http://www.eortc.be/protoc/ details.asp?protocol=08021.
- INFORM study. http://clinicaltrials.gov.
- Lee JS, Ignacio J, Yu C, et al. FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2008; 26(15_suppl): 8031.
- Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol. 2010; 28(5): 713–715.
- Miller VA, Das A, Rossi M, et al. A randomized, doubleblind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2009; 27: LBA8002.
- Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008; 26(15): 2450–2456.
- Pirker R, Pereira JR, Szczesna A, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373(9674): 1525–1531.
- Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010; 28(6): 911–917.
- O’Byrne K, Bondarenko I, Barrios C, et al. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study FLEX. J Clin Oncol. 2009; 27: 15.
- Duchnowska R. Inhibitory kinazy tyrozynowej EGFR w leczeniu przerzutów do mózgu w przebiegu niedrobnokomórkowego raka płuca. Onkol Prakt Klin. 2009; 5: 92–98.
- Kim JE, Lee DHo, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009; 65(3): 351–354.